Supernus Pharmaceuticals, Inc. (LON:0LB2)

Supernus Pharmaceuticals Statistics

Total Valuation

LON:0LB2 has a market cap or net worth of GBP 1.84 billion. The enterprise value is 1.48 billion.

Market Cap	1.84B
Enterprise Value	1.48B

Important Dates

The next estimated earnings date is Tuesday, November 4, 2025.

Earnings Date	Nov 4, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	56.07M
Shares Outstanding	n/a
Shares Change (YoY)	+3.11%
Shares Change (QoQ)	+1.39%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	48.87M

Valuation Ratios

The trailing PE ratio is 39.06 and the forward PE ratio is 22.37.

PE Ratio	39.06
Forward PE	22.37
PS Ratio	3.79
PB Ratio	2.37
P/TBV Ratio	5.41
P/FCF Ratio	13.55
P/OCF Ratio	13.47
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 13.78, with an EV/FCF ratio of 10.91.

EV / Earnings	31.43
EV / Sales	3.04
EV / EBITDA	13.78
EV / EBIT	39.22
EV / FCF	10.91

Financial Position

The company has a current ratio of 2.58, with a Debt / Equity ratio of 0.03.

Current Ratio	2.58
Quick Ratio	2.32
Debt / Equity	0.03
Debt / EBITDA	0.22
Debt / FCF	0.17
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is 6.38% and return on invested capital (ROIC) is 3.08%.

Return on Equity (ROE)	6.38%
Return on Assets (ROA)	2.39%
Return on Invested Capital (ROIC)	3.08%
Return on Capital Employed (ROCE)	4.70%
Revenue Per Employee	720,289
Profits Per Employee	69,846
Employee Count	674
Asset Turnover	0.49
Inventory Turnover	1.36

Taxes

In the past 12 months, LON:0LB2 has paid 12.89 million in taxes.

Income Tax	12.89M
Effective Tax Rate	21.50%

Stock Price Statistics

The stock price has increased by +47.39% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+47.39%
50-Day Moving Average	39.41
200-Day Moving Average	35.76
Relative Strength Index (RSI)	57.06
Average Volume (20 Days)	198

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	5.86

Income Statement

In the last 12 months, LON:0LB2 had revenue of GBP 485.47 million and earned 47.08 million in profits. Earnings per share was 0.83.

Revenue	485.47M
Gross Profit	429.80M
Operating Income	37.62M
Pretax Income	59.97M
Net Income	47.08M
EBITDA	96.51M
EBIT	37.62M
Earnings Per Share (EPS)	0.83

Balance Sheet

The company has 381.44 million in cash and 23.19 million in debt, giving a net cash position of 358.25 million.

Cash & Cash Equivalents	381.44M
Total Debt	23.19M
Net Cash	358.25M
Net Cash Per Share	n/a
Equity (Book Value)	776.54M
Book Value Per Share	13.84
Working Capital	330.28M

Cash Flow

In the last 12 months, operating cash flow was 136.54 million and capital expenditures -872,231, giving a free cash flow of 135.66 million.

Operating Cash Flow	136.54M
Capital Expenditures	-872,231
Free Cash Flow	135.66M
FCF Per Share	n/a

Margins

Gross margin is 88.53%, with operating and profit margins of 7.75% and 9.70%.

Gross Margin	88.53%
Operating Margin	7.75%
Pretax Margin	12.35%
Profit Margin	9.70%
EBITDA Margin	19.88%
EBIT Margin	7.75%
FCF Margin	27.94%

Dividends & Yields

LON:0LB2 does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-3.11%
Shareholder Yield	n/a
Earnings Yield	2.56%
FCF Yield	7.38%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

LON:0LB2 has an Altman Z-Score of 5.06 and a Piotroski F-Score of 7.

Altman Z-Score	5.06
Piotroski F-Score	7